Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer ...
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...
MedPage Today on MSN
For Your Patients: What to Know About the Newest Treatments for HR+/HER2- Breast Cancer
Resistance to initial therapy sets the stage for many other options ...
Zacks Investment Research on MSN
Roche's breast cancer drug cuts risk of death by 30% in phase III
Roche RHHBY announced positive new data from a pre-specified interim analysis of its late-stage breast cancer study on ...
Please provide your email address to receive an email when new articles are posted on . Endocrine Today has compiled a list of recent FDA news stories relating to endocrine practice. Drugs under ...
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease[1] In the Phase III trial, most patients ...
LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global endocrinology drugs market to grow at a CAGR of over 6% during the forecast period, according to their latest market research report.
The American Association of Clinical Endocrinology (AACE) has updated clinical practice guidelines for the pharmacologic management of dyslipidemia among adults. The full guidance is published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback